There are currently 150 Nasdaq-listed biotechnology companies trading at an enterprise value of or below zero, where the value of the company is equal to or less than the amount of cash on its balance sheet. This is the greatest number of businesses in this situation in the sector for 15 years.
To continue reading this article...
Join Investment Week today
Free for those involved in advising, managing and/or analysing investments or £1 per day for professionals outside of these roles.
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
